LP0200 / LEO Pharma - LARVOL DELTA

Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review. (PubMed, Am J Clin Dermatol) - "Key agents under investigation include netakimab, vunakizumab, xeligekimab, gumokimab, HB0017, CJM 112, JS005, 608, LZM012, ZL-1102, izokibep, sonelokimab, DC-806, DC-853, and LEO 153339. Both preclinical and clinical trial data for each agent are summarized, with an emphasis on their efficacy, adverse effects, immunogenicity, and future outlooks."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults (clinicaltrials.gov) - P1 | N=108 | Completed | Sponsor: LEO Pharma | Recruiting ➔ Completed | Trial completion date: Nov 2022 ➔ Jul 2022 | Trial primary completion date: Nov 2022 ➔ Jul 2022

Trial completion • Trial completion date • Trial primary completion date

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults (clinicaltrials.gov) - P1 | N=134 | Recruiting | Sponsor: LEO Pharma | Trial completion date: Jan 2022 ➔ Nov 2022 | Trial primary completion date: Jan 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults (clinicaltrials.gov) - P1; N=122; Recruiting; Sponsor: LEO Pharma; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open